CIK 0001664710
- Non-accelerated filer
- Smaller reporting company
Keros Therapeutics, Inc.
Sign in to watch- Ticker
- KROS
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- Operating
- EIN
- 811173868
- Phone
- +1 617-314-6297
- Business address
- 1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA, 02421
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $17,830
- in 3 filings, $18K under 10b5-1 plans
Net −$17,830. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-11-21 | ORBIMED ADVISORS LLC Director | Returned to the company | −140,057 | $17.75 | $2.5M | 759,155 |
| 2025-11-21 | ORBIMED ADVISORS LLC Director | Returned to the company | −74,465 | $17.75 | $1.3M | 45,057 |
| 2024-08-13 | ORBIMED ADVISORS LLC Director | Sale | −220,600 | $44.01 | $9.7M | 899,212 |
| 2024-08-13 | ORBIMED ADVISORS LLC Director | Sale | −29,400 | $44.01 | $1.3M | 119,522 |
| 2020-04-13 | ORBIMED ADVISORS LLC Director | Conversion | +744,612 | 744,612 | ||
| 2020-04-13 | ORBIMED ADVISORS LLC Director | Conversion | +148,922 | 148,922 | ||
| 2020-04-13 | ORBIMED ADVISORS LLC Director | Purchase | +375,200 | $16.00 | $6.0M | 1,119,812 |
| 2020-04-13 | ORBIMED ADVISORS LLC Director | Conversion · Series C Preferred Stock | −744,612 | 0 | ||
| 2020-04-13 | ORBIMED ADVISORS LLC Director | Conversion · Series C Preferred Stock | −148,922 | 0 |
Page 1 of 1 · 9 trades